Immune checkpoint inhibitors (ICIs), such as programmed cell death/programmed death ligand 1 (PD-1/PD-L1) inhibitors and T-lymphocyte-associated protein 4 (CTLA-4) inhibitors, have been widely used as a standard cancer treatment in recent years. Here, CD274 is linked to cancer.